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Background: Thermal injuries affect millions of adults and children worldwide and are associated with highmor-
bidity andmortality. The key determinant for the survival of burns is rapidwound healing. Large wounds exceed
intrinsic wound-healing capacities, and the currently available coverage materials are insufficient due to lack of
cellularity, availability or immunological rejection.
Methods: Using the surgically debrided tissue, we isolated viable cells from burned skin. The isolated cells cul-
tured in tissue culture dishes and characterized.
Findings:We report here that debrided burned skin, which is routinely excised from patients and otherwise con-
sidered medical waste and unconsciously discarded, contains viable, undamaged cells which show characteris-
tics of mesenchymal skin stem cells. Those cells can be extracted, characterized, expanded, and incorporated
into created epidermal-dermal substitutes to promote wound healing in immune-compromisedmice and York-
shire pigs without adverse side effects.
Interpretation: These findings are of paramount importance and provide an ideal cell source for autologous skin
regeneration. Furthermore, this study highlights that skin contains progenitor cells resistant to thermal stress.
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Thermal injuries are one of themost devastating and lethal traumata
a patient can incur, outranking the combined incidence of HIV and tu-
berculosis with over 11 million people requiring medical attention
and 265,000 fatalities per annum [1,2]. During the recent decades,
many advances have improved the outcomes of burn patients. How-
ever, the single most important factor in determining survival or
death of a burn patient is wound coverage and wound healing [3,4].
The current standard of care generally requires burn wounds excision
within 72 hours post-burn injury. This early excision is not only critical
for survival but also reduces the source of inflammatory stimuli and at-
tenuates detrimental systemic reactions including hypermetabolic re-
sponses [5,6], as well as pathologic local responses, e.g., keloid
formation or hypertrophic scarring [1,7–11]. Autologous skin grafting
is considered the gold standard for wound coverage after the removal
of the burned skin [12–15]. However, harvesting autologous skin is in-
vasive, creates a new wound in a healthy skin area, and it bears the
risk forwound complications such as pain, scarring, and delayed healing
[1,10,11,16–18]. In addition, the larger the burn, the less healthy skin re-
mains for autologous skin grafting that is limiting its availability for
grafts. These complications are indicative of the need for alternative
wound coverage materials [13,14,19,20]. However, to date, no such
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feasible coverage material exists [21–24]. Current materials are either
ineffective, cause immunologic rejections, take too long to produce suf-
ficient cell numbers, are too expensive, or are acellular [13,24].
The skin contains stem cells in a very complex structure with com-
plex function [25,26]. While an array of stem cells have been described
for the epithelial layer of the skin, little is known about dermal reconsti-
tution during skin healing [27–32]. It is reported thatfibroblast-like cells
from surrounding intact cells as well as recruitedmesenchymal progen-
itor cells are contributing to the reconstitution of dermis [33–36].More-
over, recent data is showing that myeloid lineage cells may directly
convert into the fibroblast-like cells and contribute in dermis reconsti-
tution [37,38]. After injury, these cells migrate towards the wound bed
and form a new tissue, considered granulation tissue, which is essential
forwoundhealing since itfills thewoundgap andprovides a scaffold for
epithelialization [29,32] and neovascularization [33,39]. Nevertheless,
the final phenotype of cells in granulation tissuemilieu is mesenchymal
and that suggests mesenchymal stem cell therapy as a promising treat-
ment for the management of deficient or complex wounds. Various
comparative preclinical studies using different animal models of skin
healing support this notion [30,32,40–46]. However, none of the current
stem cell sources (e.g., bone-marrow, adipose and umbilical cord) have
yet to be clinically relevant due to inherent limitations such as lack of
availability, ethical concerns, need for invasive extraction methods
and the risk of immunologic rejection for allogenic sources. Moreover,
the identity of skin fibroblast-like cells is unique, yet heterogenous
[47]. This raises the possibility that skin mesenchymal cells might be
the ideal cells for dermis reconstitution in compare with other sources
of mesenchymal stem cells.
Here, we report that severely burned skin (full-thickness burn,
third-degree burn, damage extended to the epidermis and entire der-
mis), which is routinely excised and discarded and considered as med-
icalwaste - contains viableMSC (burn-derivedmesenchymal stemcells,
BD-MSCs) that can be used for skin regeneration and wound healing.
We extracted, characterized, and expanded those cells in vitro, incorpo-
rated them into an establishedwound coveragematerial, routinely used
in the clinic. We then applied the cellular coverage material onto exci-
sional wounds in immune-incompetent mice as well as immune-
competent pigs. Our data demonstrate that BD-MSCs facilitates healing
anddecreases healing time. The thermally injured skin provides an ideal
source of mesenchymal stem cells for regenerative medicine and is of
paramount importance to burn patients.
2. Materials and methods
2.1. Tissue sampling
After surgical prep and cleaning, the surgically debrided tissue was
added to the sterile containers, wrapped carefully and transferred to
the research laboratory for further analysis.
2.2. Cell extraction and tissue culture
Burned derived-MSCs were extracted using two different methods
that both were able to successfully isolate viable mesenchymal stem
cells out of burned tissue. We used either an enzymatic cell extraction
method, for which burned skin was homogenized and incubated in col-
lagenase I (Supplement Text 1) or a conventional extraction method:
First we washed the tissue in PBS with 1% and 2% Ab/Am. Afterward,
we cut the tissue into 1 cm wide squares and placed in DMEM growth
medium made up of High Glucose Dulbecco's Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% Ab/
Am. Before placing, a few scratches were made on the dermal surface
of the skin using a surgical scalpel. That scratches enhanced the number
of isolated cells. The medium was changed every 2–3 days. When cells
began to grow out from the tissue, the tissue was removed, and adher-
ent cells continued to grow.
Cells extracted and cultured from both methods were treated the
same. Upon reaching 80% confluency, cells were resuspended in 0.05%
trypsin-EDTA for a total of one or two passages, depending on the sam-
ple. Cells were kept frozen in liquid nitrogen until the beginning of the
experiment.
2.3. Flow cytometry assay
Flow cytometrywas performed on BD-MSCs usingmarkers forMSCs
(Negative markers: CD34, CD45, and positive markers: CD73, and
CD105) by using a BD LSR II Flow Cytometer. Live cells were selected
and the CD34-/CD45- population, was gated for CD73+/CD105+. Anti-
bodies used were CD34 FITC (Invitrogen), CD45 APC/cy7 (Biolegend),
CD73 PE (eBioscience) and CD105 APC (eBioscience).
2.4. Colony forming unit-assay
In 6-well plates BD-MSCs and passage 8 of normal humanfibroblasts
were seeded in duplicates at three different cell concentrations (100,
500 and 1000 cells/100 mm). Cells were cultured for two weeks with
one change of growthmedium. They were stained with 0.5% Crystal Vi-
olet (Sigma) in methanol for 15 min at room temperature. They were
Research in context
Evidence before this study
Advances in resuscitation, wound healing, pulmonary support,
and infection have improved post-burn outcomes, but a severe
burn is still associated with significant morbidity and mortality.
While autografting is the surgical gold standard for this patients,
lack of intact skin prohibits a successful and complete
autografting when there is a large burn size.
Added value of this study
We isolated cells from a dermal component of discarded burned
skin. This tissue is usually considered “waste tissue.”The isolated
cells are viable and show characteristics of human mesenchymal
stem cells (MSCs). Formation of biomaterial sheets using these
cells and application of them onto excisional wounds of immune-
incompetent mice as well as porcine models demonstrate that
the Bd- MSCs facilitate healing and decrease healing time. Bd-
MSCs presents numerous advantages when compared to other
sources of MSCs. It does not raise the ethical issues that act as
an obstacle to embryonic or cadaverous stem cell extraction. Al-
most no patient refuses to donate these discarded tissues. More-
over, cell isolation from the burned skin is a non-invasive
procedure for the patient since removing burned skin is part of
the routine standard of care for burned patients. Furthermore,
since they are the patient's own stem cells, the chance of immu-
nological reaction and rejection is substantially low. These find-
ings are of paramount importance to the burned patients since
quick; permanent wound closure is essential in the management
of burned patients.
Implications of all the available evidence
New advances in tissue engineering using composite scaffold fab-
ricated from natural and synthetic biomaterials together with ad-
vances in 3D bioprinting provide the promising 3D
microenvironment for manufacturing skin substitutes using pa-
tients’ own burned BD-MSCs.
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washed twice with PBS then imaged for quantification. The number of
colonies and the number of colonies larger than 3 mm in diameter
were counted.
2.5. In vitro differentiation
Adipogenic differentiation: Cells were seeded in 24 well plates with
a 6000 cells/well concentration. Adipogenic cells were cultured in low
glucose DMEMsupplementedwith 10% FBS, 1% Ab/Am, 1mMof sodium
pyruvate, 0.1 mM of ascorbic acid-2-phosphate, 1% insulin-transferrin-
selenium, 100 nM of dexamethasone and 10 ng/mL of TGF-β3. Control
fibroblasts and burn derived MSCs were grown in low glucose DMEM
growth medium Cells were placed in an incubator at 37 °C in 5% CO2
for 14 days. The medium was changed twice weekly.
Osteogenic differentiation: Cellswere seeded in 24well plateswith a
6000 cells/well concentration. Osteogenic cells were cultured in low
glucose DMEM supplemented with 10% FBS, 1% Ab/Am, 0.05 mMascor-
bic acid-2-phosphate, 10 mM β-glycerophosphate and 100 nM dexa-
methasone. Control cells were cultured in DMEM growth medium for
fibroblast and burn derived MSCs. Cells were placed in an incubator at
37 °C in 5% CO2 for 21 days. The medium was changed twice weekly.
Chondrogenic differentiation: Cells were seeded at a density of
200,000 cells per 15 ml falcon tube. Chondrogenic pellets were covered
with 0.5 mL of low glucose DMEM supplemented with 10% FBS, 1% Ab/
Am, 1 mM of 3-isobutyl-1-methylxanthine, 10 μg/mL of insulin, 60 μM
of indomethacin and 1 μM of dexamethasone. Control fibroblast and
burn derived MSC pellets were covered with 0.5 mL of DMEM growth
medium. Cells were placed in an incubator at 37 °C in 5% CO2 for
35 days. The medium was changed three times weekly, being careful
not to disrupt cell pellet. After 35 days of chondrogenic differentiation,
cell pellets were removed from the 15 mL falcon tubes and placed in
10% formalin for 24 h then placed in 70% ethanol for an additional
24 h. Aggregates were afterward embedded in paraffin, cut into 5 μm
slices and placed on microscope slides.
2.6. Differentiation staining
Oil RedO staining: After twoweeks of adipogenic differentiation, the
mediumwas removed, andwells were rinsed with PBS. Cells were then
fixed in 10% formalin for 30min, rinsedwith distilled water and stained
with Oil Red O for 5 min (Sigma-Aldrich). Following multiple rinses
with water, cells were stained with hematoxylin (Sigma). Intra-
cytoplasmic lipid droplets appear in red and nuclei in dark blue.
Alizarin red staining: After threeweeks of osteogenic differentiation,
the medium was removed, and wells were rinsed with PBS. Cells were
then fixed in 10% formalin for 30 min, rinsed with distilled water and
stained with Alizarin red (Sigma-Aldrich) in the dark for 45 min. Cells
werewashedwith distilledwater prior to imaging. Calciumdeposits ap-
pear in red.
Alcian Blue Staining: For chondrogenic samples, the paraffin-
embedded slides were deparaffinized with citrosol and rehydrated
through graded ethanol to water. Slides were incubated in 1% alcian
blue 3GX (Santa Cruz Biotechnology) in 3% acetic acid in water for
30 min at RT. The stain was washed with tap water then distilled
water then counterstained with 0.1% nuclear fast red (Santa Cruz Bio-
technology). Slides were washed for 1 min in tap water then
dehydrated through increasing grades of ethanol, cleared in citrosol
and mounted with the xylene-based mounting medium.
Immunofluorescent adipogenic cell culture staining: Samples were
then fixed in 4% paraformaldehyde, permeabilized with 0.25% Triton
X-100 and incubated with anti-human rabbit perilipin antibody (Cell
Signalling). Samples were afterward incubated with a secondary anti-
rabbit biotinylated antibody then DyLight 649 streptavidin (Vector
Labs).
2.7. Control group, scaffold
Our used control is the current gold standard in burn care, a meshed
acellular bilayer scaffold consisting of bovine collagenwith a removable
silicon layer (Integra©), introduced in 1980.
2.8. In vivo experiments - mice
Ten 6–8 week-old nude mice (Jackson Laboratories) were used in
this experiment. This experiment was reviewed by the ethics commit-
tee and approved (AUP #: 15-503). Five mice randomly allocated to
the control group and five in the treatment group. All mice were placed
under isofluorane anesthetic and received two 6 mm full-thickness
punch wounds on their mid back. Each wound was surrounded with a
silicone ring (sutured tightly) to prevent wound healing through skin
contraction. Control wounds received 100 μl of Matrigel only, and treat-
mentwounds received the same volume ofMatrigel containing 110,000
BD-MSCs/wound. Matrigel was of high concentration and was applied
dropwise in liquid form and then allowed to gel. Thewound bed and sil-
icone ring were covered with Tegaderm® transparent film dressing
which adhered to the surrounding intact skin. Mice were monitored
for twelve days on a daily basis then sacrificed. Mice were injected
with 33.3mg/kg BrdU in PBS (5.5%DMSO) 8 h prior to sacrifice to detect
cell proliferation.
Skin histology: After 12 days, the scar areawith surrounding normal
skin was removed, fixed in 10% formalin and embedded in paraffin.
Briefly, we fixed the tissue specimens in 10% buffered formalin over-
night at room temperature, preserved in 70% ethanol and embedded
in paraffin. Specimens were cut into 5 μm sections. A serial section of
the scar or healing woundwas performed. The largest wound diameter
or central wound section was chosen for trichrome staining and the ad-
jacent sections were used for other Immunohistochemistry stainings.
Trichrome staining: Paraffin-embedded slides were deparaffinized
through citrosol and rehydrated through grades of ethanol for staining.
Staining solutions were from Electron Microscopy Sciences unless oth-
erwise stated. Samples were kept for one hour in Bouin's solution at
56 °C then consecutively stained in Weigert's Iron Hematoxylin Work-
ing Solution (Sigma-Aldrich), Biebrich scarlet-acid Fuchsin solution,
phosphomolybdic-phosphotungstic acid solution, and aniline blue solu-
tion. Collagen appears in blue, nuclei in black and muscle, cytoplasm
and keratin in red. Slides were observed by light microscope LeicaDM
2000 LED. The average wound size was calculated by measuring the
length of thewound bedwhich is evident by a lack of dark blue collagen
staining and thicker keratinization at the edges. The keratinocyte thick-
ness was calculated by measuring the thickness of the red keratinocyte
layer at the middle of the wound.
Immunohistochemistry: Skin wound slides were deparaffinized and
rehydrated for staining and incubated in antigen decloaker (Biocare) in
a pressure cooker at 110 °C for 4min for antigen retrieval. Sampleswere
blocked with 3% H2O2 for 10 min before antibody incubation for 1 h.
Ki67 and BrdU antibodies (Cell Signaling) were used for detection of
these proteins, as well as CD31 and CD11b in the porcine model. DNA
was denatured with HCl to allow access of the BrdU antigen, thus de-
tecting proliferating cells in thewound area. Antibodieswere visualized
throughHRPpolymer detection kits (Biocare) followed bybetazoid DAB
chromogen kit (Biocare). Slides were counterstained with hematoxylin,
dehydrated and mounted with xylene-based mounting medium. Slides
were observed by light microscope LeicaDM 2000 LED. Positive cells
were then quantified in the dermal area of the wound bed and their
density was evaluated. Error bars show the 95% confidence interval
and statistical analysis was done using the Student's t-test.
2.9. In vivo experiments - swine
Four male Yorkshire pigs (Colwell Farms, Canada) with a weight of
20–30 kg were used. This experiment was reviewed by the ethics
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committee and approved (AUP #: 16-600). We compared wound
healing in a 5 x 5 cm created full-thickness burn, excising the burned
skin wounds, treated with either acellular Integra© (n = 4) or with
Integra© containing 5.000, 200.000 or 400.000 BD-MSCs/cm2 (each
wound, n = 4). Surgical procedures and wound care was adapted
from [48]. Supplement Fig. 4 shows a schematic of the experiment
and the different wound care modalities used. In this pilot study, we
did not have location-matched controls.
BD-MSC incorporation in a control scaffold: Cultured BD-MSCs were
trypsinized, counted and resuspended in standard cell culture medium
(see above). On a sterile cell culture dish, cells were applied with a 16-
channel pipette on top of the bovine collagen of Integra©, with the sili-
cone side facing down. After cell application, scaffoldswere incubated at
37 degrees Celsius at 5% CO for 15–20min, before completely submerg-
ing them in medium and stored in a tissue incubator for 12 h. The cell
culture medium was washed off for 30 min on a Rocker. Cellularized
skin scaffolds were stored in PBS on ice for a maximum of 2 h until ap-
plication onto the wounds.
Assessmentof epithelialization:Photographsof thewounds together
with a scale bar were taken intraoperatively with each dressing change.
Epithelialization was measured from day 10 (=removal of the silicone
layer of Integra©) to day 23 (=first complete closure of a wound by ep-
ithelialization). Wemeasured from the hairline to the visible epithelial-
ization line. Measurements were done in Image J Version 1.51 for MAC.
Epithelialized Area: We measured total wound area and non-
epithelialized area. The epithelialized wound area was calculated as fol-
lows: total wound area - non-epithelialized area.
Epithelialization Speed: To take into account that due to different
wound contractions and different mechanical strains all wounds had a
slightly different size, we calculated the epithelialization speed between
day 10 and day 23 as follows: epithelialized area at day 23/days after re-
moval of silicone.
Vascularization: We measured the neovascularization of absolute
vessels, on immunohistological stainedmicroscopy slides under themi-
croscope, using the marker anti-CD31-antibody. Each sample was
assessed on three different microscopy sections with the calculated
mean, always using the same depth of the measuring point.
Inflammation: In the sameway the inflammationwas assessedusing
the anti-CD11b-antibody marker specific for monocytes, macrophages,
and granulocytes, with the following counting on each histological sam-
ple three times in the same depth from the epidermis into the dermis.
2.10. Statistical analysis and graphical representation
Statistical analysis was done via Prism GraphPad Version 5.0a for
Mac and Microsoft Excel 2016 for Mac. Two groups were compared
with an unpaired t-test, more than two groups with a one-way
ANOVA with a post-hoc Tukey test. A p-value b .05 was considered sta-
tistically significant.
All graphs are made with Prism GraphPad Version 5.0a for Mac and
display mean ± SEM.
3. Results
3.1. Discarded, severely burned skin contains viable mesenchymal stem
cells
We used excised human skin from patients that suffered at least a
third-degree burn and evaluated skin of five patients with either scald
or flame burns (Supplement Fig. 1).We extracted cells (Protocol in Sup-
plement Text 1) and plated, regardless of the etiology of the burn
trauma. 24 h after skin excision and cell extraction, an average number
of 16,140 ± 5416 viable cells per cm2 burned skin was attached to the
plastic surface of the cell culture flask (Supplement Fig. 1). Using the
non-enzymaticmethod, the cut tissue (~1 cm2) placed inDMEMgrowth
medium. We observed cell outgrowth from the skin into the tissue
culture dish regardless of the fact whether they are from the corner of
discarded burn skin or the center of discarded skin.
Flow cytometry analysis of freshly isolated live cells showed that the
majority of isolated cells are positive CD73 and CD105 while negative
for CD34 and CD45, characteristics of mesenchymal stem cells. These
cells form colonies in a colony-forming assay (Fig. 1) and could differen-
tiate into the three lineages of mesenchymal cell progeny (adipogenic,
chondrogenic, osteogenic differentiation), confirming their multipotent
capacity (Fig. 2). Since the viable cells extracted from burned skin meet
the definition criteria for mesenchymal stem cells [49], we refer those
cells as burn-derived mesenchymal stem cells (BD-MSCs).
3.2. BD-MSCs are safe to use
To address themajor safety concerns of cell therapy,we assessed the
tumor formation potential of BD-MSCs in vitro and in vivo. BD-MSCs did
not show any tumorigenic potential in soft agarose cultures nor when
injected subcutaneously into immune-incompetent mice within 20d
compared to tumorigenic cells (Fig. 3). Moreover, we observed no ad-
verse side effects - neither systemically nor locally in the 30d porcine
experiment.
3.3. BD-MSCs enhance wound healing in mice
Confirming the pluripotency and safety of BD-MSc, we evaluated the
reparative and regenerative potential of these cells in mice. Ten immu-
nodeficient athymic mice were subjected to 4 mm excisional punch bi-
opsy (1 per side, equidistant from the spine) and randomly divided into
two group of treatment and control. BD-MSCs embedded in Matrigel to
assure cell adhesion to the wound bed, while the control mice only re-
ceived Matrigel (Fig. 4A). We observed mice over 12 days to allow all
wounds to fully close. Mice treated with BD-MSCs visibly displayed
faster healing (Fig. 4B). Histological examination of the healed wounds
at day 12 post-wounding showed a significantly smaller wound size
(Fig. 4C–E), as well as a thinner keratinocyte layer (Fig. 4C, D, F) in the
BD-MSC group.
We further evaluated the effect of BD-MSC treatment on wound
healing by evaluating the granulation tissue formation and the state of
cell proliferation (Fig. 5). Granulation tissue formation and proliferation
activity usually pick up at 7 days postwounding in thiswoundmodel. At
day 12, while the control animals still showed high proliferation activ-
ity, mice received BD-MSCs have passed the pick of proliferation
phase and showed a lower proliferation profile - characteristic of late
proliferation phase and early remodeling phase.
We also stained the BD-MSC treated wounds at day 12 with HLA
class 1ABC antibody (Supplement Fig. 2). Our results show that BD-
MSCs were still present in the newly formed tissue after complete
wound closure and epithelialization. These data show that topical BD-
MSC treatment accelerated wound healing, reduced scar formation
and did not lead to adverse side effects in mice.
3.4. BD-MSCs enhance wound healing in pigs
After determination of the safety and positive effect of BD-MSC
treatment in mice, we used a porcine wound-model with 5 × 5 cm ex-
cisional wounds. Porcine wounds resemble human wound healing, the
closest next to primate-models [50,51].
For higher clinical relevance, we first incorporated BD-MSCs in the
meshed bilayer Integra© an FDA-approved, synthetic wound coverage
material scaffold considered as gold-standard in burn care [15]. BD-
MSCs could be incorporated easily in a straightforward protocol, by pi-
petting them onto the bovine collagen layer which was later placed di-
rectly onto the wound bed (Supplement Fig. 3). The incorporated BD-
MSCs displayed complete attachment to the material and a healthy
cell morphology 12 h after pipetting.
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We placed the scaffold containing BD-MSC on the 5 × 5 cm full-
thickness excisionalwounds (n=4 for each group) on the back of York-
shire pigs (n = 4) and compared with acellular, conventional Integra©
following an established wound care protocol [48] (Supplement Fig. 4).
BD-MSC treatment of excisional wounds in the porcine model
showed the pro-wound healing properties of BD-MSCs obtained in the
previous murine study without any adverse side effects. Although a ro-
bust phenotypewas not observed, continuous evaluation of thewounds
showed that wounds treated with BD-MSC exhibit an accelerated epi-
thelialization time and a larger re-epithelialized area (Fig. 6).We started
to assess the extent of re-epithelialisation after the silicone (bi-) layer of
Integra© peeled off (day 10). Beside enhanced re-epithelialization, we
observed more number of blood vessels in the dermal component of
reconstituted skin, another characteristic of enhanced skin healing
(Fig. 7). No safety concern or adverse effect could be detected inwounds
treated with BD-MSCs.
4. Discussion
We show for the first time that full-thickness burned skin that is
usually discarded to avoid further morbidities contains viable
mesenchymal skin stem cells. These cells are a readily available source
of skin stem cells and can be extracted, expanded in vitro, and used as
an adjunctive to existingwound coveragematerials in a straightforward
and a cost-effective incorporation process. Furthermore, these findings
represent a potential new skin stem cell therapy source originating
from the injured organ itself. Unfortunately, the current standard of
care suggests discarding this invaluable source of stem cells as amedical
waste while this unexploited commodity might change a wound care
paradigm. We demonstrated the wound healing potential of BD-MSCs
in two different animal models mice and swine without any adverse
side effects. This is an exciting discovery for stem cell research as well
as the burn community since this will change the way we manage and
practice stem cell therapy in burns and potentially complex wound
care in the future.
BD-MSCs presents with numerous advantages when compared to
other sources of MSCs in the current wound healing treatment. They
do not raise the ethical issues that represent an obstacle to embryonic
or cadaverous stem cell extraction. Almost no patient refuses to donate
these discarded tissues making such therapies universally applicable.
Furthermore, cell isolation from burned skin is a non-invasive with no
added risk to the patient since debridement of affected burned tissues
Fig. 1. Burn derived dermal cells show characteristics of mesenchymal progenitor cells. Flow cytometry of isolated cells from discarded burned skin is showing thatmajority of these cells
(88%) are positive for mesenchymal markers CD73 and CD105. The left panel is unstained while the right panel is a representative of stained cells. Note that CD34+/CD45+ cells were
gated out before analyzing. (B) Colony forming assay shows a significant increase in the number of colonies formed in burn derived cells (BD-MSCs) compared with that formed from
high passage fibroblasts (FBs). Graphics show MEAN ± SEM.
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is part of routine and therapeutic practice. Consequently, the greater the
body surface affected by burn injury the increased need for stem cells to
regenerate and replace the lost skin and concomitantly, the higher the
amount of excised skin is that can be potentially used to extract the
BD-MSCs. Moreover, since they are patient's own skin stem cells, the
chance of immunological reaction and rejection is negligible. This
autologous availability marks a stark difference to adipose tissue, bone
marrow MSC, umbilical cord stem cells in terms of harvesting and ex-
traction, which lead to discomfort, pain and a long recovery time as
well as fear and ethnically concern, despite an advantageous promotion
of wound healing [9,14,19,30,32]. Moreover, through lineage tracing
and transplantation assays, it is shown that mesenchymal cells within
Fig. 2. Burn derived dermal cells differentiate into the three lineages of mesenchymal stem cell progeny. (A-B) Oil red O and Perilipin staining show enhanced adipogenesis (fat deposits
markedwith an arrow) inBB-MSCs comparedwith high passage fibroblast. (C) Quantification of area stainedpositive for Oil RedO. (D)AlizarinRed staining shows an increasednumber of
calcium-rich deposit formation (arrow) inBD-MSCs comparedwith thenumber of depositswhich formed fromhighpassage fibroblasts (FBs). (E) Alcian Blue staining shows enhanced the
number and bigger area of alcianophilic regions (arrow) in BD-MSCs cultured in chondrogenic media. (F) Quantification of number of deposits in D. Graphics showMEAN± SEM.
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the skin are diverse and heterogeneous, each has a different suscepti-
bility [37,39,47,52–56]. That raise the possibility that the ideal source
of stem cells for regenerating dermis should arise from the dermis,
likely a distinct population of cell within these cell type, and that
questions the suitability of using other sources in regenerating dermis,
considering their versatile developmental lineage. During the last de-
cade, there has been an exponential increase of potential skin stem
cell sources in pre- and clinical studies reported in literature
[27,29–32]. However, to date, we still lack an ideal source for the ex-
traction and use of those cells in regenerative medicine despite the
surge of research in the field. Although MSCs are present in the intact
human dermis, lack of healthy donor site limits feasibility of using
these cells for large burns. The autologous source of burned tissue
overcomes this lack of availability, demonstrating macroscopically bet-
ter homogenous wound healing compared with the current gold-
standard in burn care, as well as less scarring, increased vasculariza-
tion and decreased inflammation.
MSCs are generally considered to be safe. However, there are stud-
ies reporting that MSC treatment can lead to adverse effects such as
pneumonia and the facilitation of cancer [57,58]. BD-MSCs derived
from the patient's own skin and can be re-transplanted after a suffi-
cient expansion in vitro. Since donor cells come from the patient
themselves and additionally we did not see any adverse effects or
tumor formation in vitro or in vivo the risks are maximally mitigated
making BD-MSCs an elegant source for stem cell therapy. These BD-
MSCs can be integrated easily and cost-effectively in an already widely
used and FDA-approved wound coverage material or any other scaf-
fold for many clinical purposes. We also explored the incorporation
of BD-MSCs in a variety of other wound dressings with different appli-
cation techniques. BD-MSCs have consistently shown good integration
without cell-loss or reduction of proliferation. We were able to extract
skin-derived stem cells and integrate them efficiently into skin substi-
tutes that can be placed in the same location where the extracted
stem cells come from. This gives hope that we are one step further to-
wards the end-goal of cell therapy in skin regeneration - the creation
of an off-shelf skin that only needs two components: a skin scaffold
and stem cells [59,60]. Moreover, the isolated cells will be applied to
the same location of extraction, and this increases the chance of suc-
cessful grafting, considering the nonhomogeneity of fibroblast-like
cells in a different part of the skin. Whether this mesenchymal cells
can be used as a source for epithelial cells of the skin, needs further
research [30,32,61–63]
The murine study showed accelerated wound healing and a signifi-
cant reduction in scarring
indicated by the reduced size of granulation tissue and a reduced
thickness of the keratinocyte layer. This is promising considering that
burn patients not only suffer from delayed wound closure but also de-
velop excessive scarring. The debilitating contracture is one of the
major contributors to a reduced quality of life in burn survivors
[11,59,64]
In our study,we could detect humanBD-MSCs in the scar/wound tis-
sue ofmice after completewound closure. However, it is unclear if those
cells were still in their MSC-state or if they could integrate and maybe
further differentiate and therefore fully regenerate the skin. Most stud-
ies did not find a long-term survival of foreignMSCs inwoundswhich is
mainly attributed to the harsh wound environment [65] and
Fig. 3. Burn derived dermal cells are non-tumorigenic. (A, B) BD-MSCs did not cause In vitro tumor formation in soft agarose after 20 d (arrow: tumor colony in the cancer cell group). (C,
D) No tumor formation was observed in the BD-MSC group within 20 d in vivo after subcutaneous injection in athymic mice (arrow: visible tumor in the cancer cell group).
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differentiation potential. Further studies need to answer those impor-
tant questions.
Our porcine study showed an increased epithelialization speed and
area, confirming the acceleration of wound healing by BD-MSC treat-
ment. Furthermore, a significantly higher number of new blood vessels
have been observed in wounds treatedwith BD-MSC. More study is un-
derway to evaluate whether the enhanced neovascularisation is the
result of general enhanced wound healing or there is a direct effect of
BD-MSCs on neovascularisation.
Beside the translational advantages of BD-MSCs, it is interesting that
a group of cells in the dermis with stemness characteristics resist the
heat after burn. It is possible that stress response in dermal mesenchy-
mal stem cells make them resistant to this stress. Burn is accompanied
by hypermetabolism that is characterized by a considerable increase
Fig. 4. Burn derivedMSCs enhance skin healing. Schematic of in vivo animal experiment. (B) Time coursemeasurement of wounded skin shows faster healing in excisional biopsieswhich
were treated with BD-MSCs compared with control group. Note the arrows in days 8 and 12 post biopsy. (C–D) Trichrome staining of healed skin 12 days post wounding shows smaller
scar size and thinner keratinocyte layer in the wounds exposed to BD-MSCs. Arrows show the border of normal skin with the healing bed and arrowheads mark the newly formed
keratinocyte layer. (E) Quantification of wound size. (F) Quantification of keratinocyte layer thickness. Graphics show MEAN± SEM.
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in resting energy expenditure and substantial whole-body catabolism,
all associated with mitochondrial alteration [66]. Whether the mito-
chondrial changes in the dermal stem cells selectively protect them is
the subject of a new line of research andneeds further research to verify.
Nonetheless, recent studies indicated that mitochondrial dynamics is
associated with self-renewal and resistance to differentiation in some
stem cells [67,68].
Burn-derived stem cells are a promising new source of skin stem
cells for regenerativemedicine and burn-woundmanagement.Without
being limited by the common obstacles of stem cell therapies and its
availability, this autologous method will revolutionize the way we
treat burn patients and potentially patients with complex wounds.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.10.014.
Fig. 5. Burn derivedMSCs shorten the proliferative phase of skin healing. (A) Ki67 staining of healed skin 12 days post wounding shows significantly less Ki67+ cells in the healing bed of
wounds treated with BD-MSCs. Arrows show Ki67+ cells. (B) Quantification of the number of Ki67 positive cells. (C) BrdU incorporation of healed skin 12 days post wounding shows
significantly less BrdU incorporation in the healing bed of wounds treated with BD-MSCs. Arrows show cells which are incorporated with BrdU. (D) Quantification of the number of
BrdU-positive cells. Graphics showMEAN± SEM.
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Fig. 6. BD-MSCs improved re-epithelialization and neovascularization in procine wounds. (A) The total epithelialized area after 23 days was higher in BD-MSC treated wounds. (B) The
overall epithelialization speed (cm2/day) assessed between day 10 and 23 was higher in the BD-MSC group. (C) Representative wound images of the two groups on day 10, day 17,
and day 23 (Blue arrow: start of wound edge; Black arrow: epithelialization boarder, red arrow: scar, contracture), with macroscopically more homogenous wound healing in the BD-
MSC group. Graphics show MEAN ± SEM. (D, E) CD31 stained healed skin 28 days post wounding shows significantly more blood vessels in the granulation tissue of BD-MSC group.
(E) Quantification of the number of CD31 positive vessels. (Graphics show MEAN ± SEM.
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